ArticleCardiovascular therapeutics2025
Knockdown of LncRNA CCAT1 Attenuates ox-LDL-Induced Inflammation in THP1-Derived Macrophages via the miR-296-3p/FOSL1 Axis.
Article in Cardiovascular therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Knockdown of LncRNA CCAT1 Attenuates ox-LDL-Induced Inflammation in THP1-Derived Macrophages via the miR-296-3p/FOSL1 Axis.Cardiovascular therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage-driven inflammation, induced by dysfunctional lipid metabolism, is a pivotal process in the pathogenesis of atherosclerosis (AS). While long noncoding RNAs (LncRNAs) are established regulators, the specific mechanisms governing their roles remain largely uncharacterized. Here, we demonstrate that the LncRNA colon cancer-associated transcript 1 (CCAT1) is significantly upregulated in THP1-derived macrophages upon stimulation with oxidized low-density lipoprotein (ox-LDL). Silencing LncRNA CCAT1 markedly attenuated the ox-LDL-induced inflammatory response, establishing its proinflammatory function. Mechanistically, we identified miR-296-3p as a direct downstream target of LncRNA CCAT1, which acts as a molecular sponge. This interaction was validated by dual-luciferase and RNA pull-down assays. Furthermore, we show that miR-296-3p suppresses inflammation by directly targeting the mRNA of FOS-like antigen 1 (FOSL1). Crucially, overexpression of LncRNA CCAT1 increased FOSL1 levels, confirming this regulatory axis. Collectively, our findings delineate a novel pro-inflammatory pathway where LncRNA CCAT1 promotes macrophage inflammation by sponging miR-296-3p, thereby derepressing its target FOSL1. Therefore, targeting LncRNA CCAT1 represents a promising therapeutic strategy for treating atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.